

**For the use only of Registered Medical Practitioner**

**1. Generic Name & Brand Name**

Glycerol Syrup

Tixylix® G

**2. Qualitative and Quantitative Composition:**

Each 5 ml syrup contains:

Glycerol I.P.....0.75 ml

Excipients.....q.s.

Flavoured Syrup base.....q.s.

**3. Dosage Form & strength**

Refer section 1 & 2

**4. Clinical particulars**

**4.1 Therapeutic indication**

Dry Cough

**4.2 Posology and method of administration**

**Posology**

**Children 3 months to under 1 year** - 5ml three to four times a day.

**Children 1 year to 5 year** - 10 ml 3 to 4 times a day.

**Not recommended below 3 months.**

**4.3 Contraindications**

Hypersensitivity to any of the ingredients.

**4.4 Special warnings and precautions for use**

Do not give the syrup if a child is allergic (hypersensitive) to any of the ingredients of this syrup. Patients with rare hereditary problems of fructose intolerance, glucose galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. If symptoms persist for more than 3 days or get worse, patients should stop use and consult a doctor.

**4.5 Drug Interactions**

No clinically significant interactions known.

**4.6 Use in special populations (Pregnancy, Nursing woman, Pediatric use, Geriatric use)**

No data are available for glycerol on exposed pregnancies or use during lactation. Caution should be exercised when prescribing during pregnancy.

**4.7 Effects on ability to drive and use machines**

This product has no or negligible influence on the ability to drive and use machines.

Version 2.0, dated 16-Apr-26

Replaces: Version 1.0, dated 20-Aug-24

#### **4.8 Undesirable effects**

Glycerol may cause diarrhoea in overdose.

#### **4.9 Overdose**

Overdosage with this product may possibly cause diarrhoea. Treatment should be symptomatic.

### **5. Pharmacological properties**

#### **5.1 Mechanism of action-**

Glycerol has demulcent properties and may possibly block sensory cough receptors in the respiratory tract.

#### **5.2 Pharmacodynamic Properties**

Glycerol has demulcent properties and may possibly block sensory cough receptors in the respiratory tract.

#### **5.3 Pharmacokinetic properties**

##### **Absorption**

Glycerol is readily absorbed from the gastrointestinal tract.

##### **Distribution**

Glycerol combines with free fatty acids in the liver to form triglycerides which are distributed to adipose tissues.

##### **Metabolism**

Glycerol undergoes extensive metabolism principally in the liver and to a lesser extent in the kidneys. Glycerol is metabolised to glucose or glycogen or oxidised to carbon dioxide and water.

##### **Elimination**

It may also be excreted in the urine unchanged.

### **6. Nonclinical properties**

Non-clinical data reveal no special hazard for humans based on studies of repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.

#### **6.1 Animal Toxicology or Pharmacology**

Not known

### **7. Description**

Tixylix G is supplied for oral administration.

Each 5 ml syrup of Tixylix G contains Glycerol 0.75 ml.

### **8. Pharmaceutical particulars**

#### **8.1 Incompatibilities-**

NA.

Version 2.0, dated 16-Apr-26

Replaces: Version 1.0, dated 20-Aug-24

## **8.2 Shelf Life**

Refer pack

## **8.3 Packaging Information**

Refer Pack

## **8.4 Storage condition and handling instructions**

Refer pack

## **9. Patient Counseling Information-**

Always give glycerol syrup exactly as your doctor has told you. Do not give to children under 3 months. Do not give more than the amount recommended above. If symptoms do not go away within 3 days talk to your doctor.

## **10. Details of manufacturer**

Refer Pack for manufacturer details

Marketed by:

**Abbott Healthcare Pvt. Ltd.**

Angel Space, Bldg. D-4, Gala No. 1 to 3 & 11 to 13 Ground Floor, 101 to 106 & 111 to 116 First Floor, 201 to 206 & 211 to 216 2<sup>nd</sup> Floor, Pimplas, Dist. Thane, Bhiwandi - 421 302, Maharashtra, India.

® Regd. Trade Mark of Sanofi

## **11. Details of permission or licence number with date**

Refer Pack for Permission/License details

## **12. Date of revision**

Version 2.0, dated 16-Apr-26

For Product Complaints/Adverse events or Queries please write to **[webmasterindia@abbott.com](mailto:webmasterindia@abbott.com)**

Version 2.0, dated 16-Apr-26

Replaces: Version 1.0, dated 20-Aug-24